Medtronic FY26 Revenue Hits $36.36B, Cardiac Ablation Soars 78% Globally
MDT is trading near its 52-week low of $73.31 (7.9% above the low) on elevated volume (2.2× avg).
Summary
Medtronic reported full fiscal year 2026 revenue of $36.36 billion, with net income of $4.84 billion and diluted EPS of $3.73. Cardiac sales reached $3.8 billion, driven by a significant 78% global increase in Cardiac Ablation Solutions, including a 124% jump in the U.S. This news follows the company's 10-K filing yesterday, which reported an 8% increase in net sales for fiscal year 2026. The strong performance in Cardiac Ablation, particularly the triple-digit growth in the U.S., indicates successful adoption of new products like PulseSelect and Affera System, which could be a significant growth engine for the company.
At the time of this announcement, MDT was trading at $79.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $101.9B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.